Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity

Guardado en:

Detalles Bibliográficos
Autores principales:	Shahram Salek-Ardakani, Wenjing Yang, Sheng Ding, Shih-Hsun Chen, Pawel K Dominik, Jessica Stanfield, Nadia Kurd, Ryan Llewellyn, Jonathan Heyen, Carole Wang, Zea Melton, Thomas Van Blarcom, Kevin C Lindquist, Javier Chaparro-Riggers
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/3920fe53e43c44dd89bb0d4a1c33ff53
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3920fe53e43c44dd89bb0d4a1c33ff53
record_format	dspace
spelling	oai:doaj.org-article:3920fe53e43c44dd89bb0d4a1c33ff532021-11-22T10:00:06ZDual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity10.1136/jitc-2021-0034642051-1426https://doaj.org/article/3920fe53e43c44dd89bb0d4a1c33ff532021-10-01T00:00:00Zhttps://jitc.bmj.com/content/9/10/e003464.fullhttps://doaj.org/toc/2051-1426Shahram Salek-ArdakaniWenjing YangSheng DingShih-Hsun ChenPawel K DominikJessica StanfieldNadia KurdRyan LlewellynJonathan HeyenCarole WangZea MeltonThomas Van BlarcomKevin C LindquistJavier Chaparro-RiggersBMJ Publishing GrouparticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJournal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Shahram Salek-Ardakani Wenjing Yang Sheng Ding Shih-Hsun Chen Pawel K Dominik Jessica Stanfield Nadia Kurd Ryan Llewellyn Jonathan Heyen Carole Wang Zea Melton Thomas Van Blarcom Kevin C Lindquist Javier Chaparro-Riggers Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
format	article
author	Shahram Salek-Ardakani Wenjing Yang Sheng Ding Shih-Hsun Chen Pawel K Dominik Jessica Stanfield Nadia Kurd Ryan Llewellyn Jonathan Heyen Carole Wang Zea Melton Thomas Van Blarcom Kevin C Lindquist Javier Chaparro-Riggers
author_facet	Shahram Salek-Ardakani Wenjing Yang Sheng Ding Shih-Hsun Chen Pawel K Dominik Jessica Stanfield Nadia Kurd Ryan Llewellyn Jonathan Heyen Carole Wang Zea Melton Thomas Van Blarcom Kevin C Lindquist Javier Chaparro-Riggers
author_sort	Shahram Salek-Ardakani
title	Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
title_short	Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
title_full	Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
title_fullStr	Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
title_full_unstemmed	Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
title_sort	dual checkpoint blockade of cd47 and pd-l1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
publisher	BMJ Publishing Group
publishDate	2021
url	https://doaj.org/article/3920fe53e43c44dd89bb0d4a1c33ff53
work_keys_str_mv	AT shahramsalekardakani dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunity AT wenjingyang dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunity AT shengding dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunity AT shihhsunchen dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunity AT pawelkdominik dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunity AT jessicastanfield dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunity AT nadiakurd dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunity AT ryanllewellyn dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunity AT jonathanheyen dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunity AT carolewang dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunity AT zeamelton dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunity AT thomasvanblarcom dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunity AT kevinclindquist dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunity AT javierchaparroriggers dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunity
_version_	1718417787266793472

Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity

Ejemplares similares